DURHAM, N.C. --(BUSINESS WIRE)--Jul. 8, 2024-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies, today announced that the company will present at the upcoming JonesTrading